# Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease 

Source: https://onco.cc/trials/nct05409066/  
OnCo record `nct05409066` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Epcoritamab, Rituximab, Lenalidomide in follicular lymphoma, run by Genmab, active and no longer recruiting.

## Summary

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma is a phase 3 interventional study registered as NCT05409066 by Genmab, with 549 participants enrolled, started 2022-09-20 and due to reach its primary completion in 2029-12. Interventions recorded: Epcoritamab, Rituximab, Lenalidomide. Conditions listed: Follicular Lymphoma (FL). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT05409066
- Phase: 3
- Setting: A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination With Rituximab and Lenalidomide (R2) Compared to R2 in Subjects With Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
- Sponsor: Genmab
- Enrolled: 549

## Sources

- ClinicalTrials.gov NCT05409066: https://clinicaltrials.gov/study/NCT05409066

## Connected records

- cancers: [Follicular lymphoma](https://onco.cc/cancers/follicular-lymphoma/)
- drugs: [Epcoritamab](https://onco.cc/drugs/epcoritamab/), [Lenalidomide](https://onco.cc/drugs/lenalidomide/), [Rituximab](https://onco.cc/drugs/rituximab/)
- companies: [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct05409066.json